DK1453517T3 - Farmaceutiske formuleringer med platinderivat - Google Patents

Farmaceutiske formuleringer med platinderivat

Info

Publication number
DK1453517T3
DK1453517T3 DK02787779T DK02787779T DK1453517T3 DK 1453517 T3 DK1453517 T3 DK 1453517T3 DK 02787779 T DK02787779 T DK 02787779T DK 02787779 T DK02787779 T DK 02787779T DK 1453517 T3 DK1453517 T3 DK 1453517T3
Authority
DK
Denmark
Prior art keywords
pharmaceutical formulations
platinum derivative
platinum
derivative
formulations
Prior art date
Application number
DK02787779T
Other languages
Danish (da)
English (en)
Inventor
Sara Lauria
Alessandro Martini
Cristina Ciocca
Original Assignee
Pharmacia Italia Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21744006&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1453517(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia Italia Spa filed Critical Pharmacia Italia Spa
Application granted granted Critical
Publication of DK1453517T3 publication Critical patent/DK1453517T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DK02787779T 2001-12-06 2002-11-22 Farmaceutiske formuleringer med platinderivat DK1453517T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/010,122 US6476068B1 (en) 2001-12-06 2001-12-06 Platinum derivative pharmaceutical formulations

Publications (1)

Publication Number Publication Date
DK1453517T3 true DK1453517T3 (da) 2006-06-19

Family

ID=21744006

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02787779T DK1453517T3 (da) 2001-12-06 2002-11-22 Farmaceutiske formuleringer med platinderivat

Country Status (42)

Country Link
US (3) US6476068B1 (pt)
EP (1) EP1453517B1 (pt)
JP (1) JP2005515202A (pt)
KR (1) KR100941210B1 (pt)
CN (1) CN100540006C (pt)
AP (1) AP1760A (pt)
AR (1) AR037629A1 (pt)
AT (1) ATE317260T1 (pt)
AU (1) AU2002352105B2 (pt)
BR (1) BR0214757A (pt)
CA (1) CA2468916C (pt)
CO (1) CO5580776A2 (pt)
CR (1) CR7362A (pt)
CY (1) CY1105608T1 (pt)
DE (1) DE60209145T2 (pt)
DK (1) DK1453517T3 (pt)
EA (1) EA008090B1 (pt)
EC (1) ECSP045140A (pt)
ES (1) ES2258661T3 (pt)
GE (1) GEP20063895B (pt)
HK (1) HK1072002A1 (pt)
HR (1) HRP20040514A2 (pt)
HU (1) HUP0402217A3 (pt)
IL (2) IL162348A0 (pt)
IS (1) IS2580B (pt)
MA (1) MA27153A1 (pt)
ME (1) MEP10408A (pt)
MX (1) MXPA04005423A (pt)
MY (1) MY134422A (pt)
NO (1) NO330159B1 (pt)
NZ (1) NZ533383A (pt)
OA (1) OA12739A (pt)
PL (1) PL206755B1 (pt)
PT (1) PT1453517E (pt)
RO (1) RO121509B1 (pt)
RS (1) RS50360B (pt)
SI (1) SI21493A (pt)
TN (1) TNSN04104A1 (pt)
TW (1) TW200409640A (pt)
UA (1) UA77728C2 (pt)
WO (1) WO2003047587A1 (pt)
ZA (1) ZA200404525B (pt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040186172A1 (en) * 2001-07-02 2004-09-23 Houssam Ibrahim Oxaliplatin active substance with a very low content of oxalic acid
CA2388352A1 (en) * 2002-05-31 2003-11-30 Voiceage Corporation A method and device for frequency-selective pitch enhancement of synthesized speed
US20040022842A1 (en) * 2002-06-03 2004-02-05 Mebiopharm Co., Ltd. Liposome preparations containing oxaliplatin
DE10314377A1 (de) * 2003-03-28 2004-10-07 Stada Arzneimittel Ag Gebrauchsfertige Oxaliplatin-Lösungen
EP2243480A1 (en) * 2003-08-28 2010-10-27 Mayne Pharma Pty Ltd Pharmaceutical formulations comprising oxaliplatin and an acid.
GB2441445B (en) * 2003-08-28 2008-04-23 Mayne Pharma Ltd Acid containing oxaliplatin formulation
CA2544186A1 (en) * 2003-11-07 2005-05-26 Chiron Corporation Inhibition of fgfr3 and treatment of multiple myeloma with benzimidazole quinolinones
US7795205B2 (en) * 2004-04-12 2010-09-14 Canyon Pharmaceuticals, Inc. Methods for effecting regression of tumor mass and size in a metastasized pancreatic tumor
WO2005120480A1 (ja) * 2004-06-09 2005-12-22 Taiho Pharmaceutical Co., Ltd. 抗腫瘍効果増強剤、抗腫瘍剤及び癌治療方法
TW200617014A (en) * 2004-07-12 2006-06-01 Sicor Inc Cis-diiodo-(trans-l-1,2-cyclohexanediamine) platinum (Ⅱ) complex and processes for preparing high purity oxaliplatin
US20060063720A1 (en) * 2004-09-22 2006-03-23 Edgar Schridde Oxaliplatin solution concentrate
US20060063833A1 (en) * 2004-09-22 2006-03-23 Edgar Schridde Ready-to-use oxaliplatin solutions
DE102004052877B4 (de) * 2004-11-02 2008-06-19 Ebewe Pharma Ges.M.B.H. Nfg.Kg Stabile wässrige Formulierungen eines Platin-Derivats
CN1311818C (zh) * 2004-11-22 2007-04-25 山东蓝金生物工程有限公司 一种抗实体肿瘤的药物组合物
DE102004063764A1 (de) * 2004-12-29 2006-07-13 Hexal Ag Kunststoff-Flasche für Oxaliplatin
JP2006248978A (ja) 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
DE602005014393D1 (de) * 2005-03-28 2009-06-18 Dabur Pharma Ltd Stabile pharmazeutische zusammensetzungen aus antitumoralen platin-(ii)-mitteln
ES2440799T3 (es) * 2005-05-13 2014-01-30 Novartis Ag Métodos para tratar cáncer resistente a los fármacos
DE102005038347A1 (de) * 2005-08-11 2007-02-15 Hexal Ag Herstellung einer Oxaliplatin-Lösung und Behälter sowie Behälter-Set mit der Lösung
WO2007029268A2 (en) * 2005-09-05 2007-03-15 Dabur Pharma Limited Stable oxaliplatin formulation
PT1957074E (pt) * 2005-11-29 2014-06-25 Novartis Ag Formulações de quinolinonas
US20090076139A1 (en) * 2007-09-19 2009-03-19 Protia, Llc Deuterium-enriched oxalplatin
WO2009087660A1 (en) 2007-11-12 2009-07-16 Intas Pharmaceuticals Limited Stable oxaliplatin composition for parenteral administration
US20090221622A1 (en) * 2008-02-29 2009-09-03 Eagle Pharmaceuticals, Inc. Topotecan ready to use solutions
US9023834B2 (en) * 2008-11-13 2015-05-05 Taigen Biotechnology Co., Ltd. Lyophilization formulation
RU2563997C2 (ru) 2009-09-21 2015-09-27 Джей ДаблЮ ФАРМАСЬЮТИКАЛ КОРПОРЭЙШН Наночастицы оксалиплатина и способ их получения
US9387152B2 (en) 2010-06-28 2016-07-12 The General Hospital Corporation Blood substitutes and uses thereof
CN102274171A (zh) * 2011-08-04 2011-12-14 上海希迪制药有限公司 一种奥沙利铂注射剂
EP2874605A1 (en) 2012-07-18 2015-05-27 Onyx Therapeutics, Inc. Liposomal compositions of epoxyketone-based proteasome inhibitors
JP5929607B2 (ja) * 2012-08-06 2016-06-08 ニプロ株式会社 オキサリプラチン製剤
CN102885765B (zh) * 2012-10-25 2013-11-06 哈药集团生物工程有限公司 一种盐酸伊立替康注射液及其制备方法
US10098813B2 (en) 2014-09-03 2018-10-16 Sun Pharmaceutical Industries Limited Perfusion dosage form
KR101683635B1 (ko) * 2014-12-29 2016-12-09 가천대학교 산학협력단 락테이트 금속염을 포함하는 암 치료용 약학 조성물
KR102293907B1 (ko) * 2015-06-30 2021-08-26 한미약품 주식회사 이리노테칸 함유 경구용 고형제제 및 그 제조방법
BR112018016287A2 (pt) 2016-02-09 2018-12-18 Sun Pharmaceutical Ind Ltd sistema de perfusão, método para administrar diretamente a um paciente em necessidade do mesmo uma dose de um fármaco antineoplásico e recipiente de perfusão
EP3538546A1 (en) 2016-11-14 2019-09-18 Novartis AG Compositions, methods, and therapeutic uses related to fusogenic protein minion
SG11202006601VA (en) 2018-01-12 2020-08-28 Metimedi Pharmaceuticals Co Ltd Methods of treating chronic inflammatory diseases
KR101998246B1 (ko) 2018-08-22 2019-07-10 주식회사 메타파인즈 금속이온에 결합된 이온화합물을 포함하는 암 치료용 약학 조성물

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6041077B2 (ja) 1976-09-06 1985-09-13 喜徳 喜谷 １，２‐ジアミノシクロヘキサン異性体のシス白金（２）錯体
US5041578A (en) * 1988-11-22 1991-08-20 Board Of Regents, The University Of Texas System Water soluble 1,2-diaminocyclohexane platinum (IV) complexes as antitumor agents
EP1393730A3 (en) 1991-11-15 2004-03-17 Smithkline Beecham Corporation Combination chemotherapy involving topotecan and a platinum coordination compound
JPH0776230B2 (ja) 1992-01-13 1995-08-16 田中貴金属工業株式会社 白金化合物の製造方法
JP2673331B2 (ja) 1993-01-12 1997-11-05 田中貴金属工業 株式会社 光学的に高純度なシス―オキザラート（トランス―１―１，２―シクロヘキサンジアミン）白金（▲ｉｉ▼）
JPH06287021A (ja) 1992-04-22 1994-10-11 Tanaka Kikinzoku Kogyo Kk 光学活性な白金錯化合物の光学的分割方法
AU5416394A (en) 1992-11-24 1994-06-22 Debiopharm S.A. Cisplatinum/oxaliplatinum combination
DK0674510T3 (da) * 1992-11-27 1999-05-10 Napro Biotherapeutics Inc Injicerbart præparat omfattende paclitaxel
JP3025602B2 (ja) 1993-05-21 2000-03-27 デビオファーム エス．アー． 光学的に高純度なシス−オキザラート（トランス−ｌ−１，２−シクロヘキサンジアミン）白金（ＩＩ）錯体の製造方法
US5455270A (en) * 1993-08-11 1995-10-03 Bristol-Myers Squibb Co. Stabilized solutions of platinum(II) antitumor agents
ES2152412T3 (es) 1994-08-08 2001-02-01 Debiopharm Sa Preparacion farmaceuticamente estable de oxaliplatino.
EP0715854B1 (en) 1994-11-11 2003-09-10 Debiopharm S.A. Carcinostatic compositions containing cis-oxaliplatinum and one or more other compatible carcinostatic substances
US5919816A (en) 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
AU4842996A (en) * 1995-02-28 1996-09-18 Yoshinori Kidani Novel platinum (iv) complexes, process for producing the same, and carcinostatic agents containing the same
US5776959A (en) 1995-06-05 1998-07-07 Washington University Anticonvulsant and anxiolytic lactam and thiolactam derivatives
EP0897389B1 (fr) * 1996-03-11 2002-07-03 Yoshinori Kidani Complexes de platine dinucleaires, procede pour leur preparation et compositions pharmaceutiques en contenant
JP3154399B2 (ja) 1996-07-04 2001-04-09 デビオファーム エス．アー． 白金化合物の製造方法
DK0929293T3 (da) 1996-08-23 2004-02-02 Sequus Pharm Inc Liposomer indeholdende en cisplatinforbindelse
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
IL131008A (en) 1997-02-05 2003-06-24 Upjohn Co Lipid complexes and liposomes of highly insoluble platinum complex dicarboxylate
PT1014990E (pt) 1997-03-07 2006-11-30 Sanofi Aventis Us Llc Associação antitumoral de 1, 4-dióxido de 3-amino-1,2,4-benzotriazina/paclitaxel/platina.
GB9727523D0 (en) 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Alpha-aminoamide derivatives useful as analgesic agents
GB9804013D0 (en) * 1998-02-25 1998-04-22 Sanofi Sa Formulations
US6866857B1 (en) 1998-10-14 2005-03-15 Debiopharm S.A. Oxalipatinum preparation packaging
AU768169B2 (en) 1999-08-30 2003-12-04 Debiopharm S.A. Pharmaceutically stable oxaliplatinum preparation for parenteral administration
AU2001240001A1 (en) 2000-03-08 2001-09-17 Bristol-Myers Squibb Company Oral dosage form for administration of the combination of tegafur, uracil, folinic acid, and oxaliplatin and method of using the same
SE0003026D0 (sv) * 2000-08-25 2000-08-25 Kerstin Sunnerheim Use for conifer sapling protection

Also Published As

Publication number Publication date
EA200400777A1 (ru) 2004-12-30
AP1760A (en) 2007-07-18
AU2002352105B2 (en) 2009-12-03
CA2468916A1 (en) 2003-06-12
CA2468916C (en) 2009-01-20
PL370254A1 (en) 2005-05-16
ECSP045140A (es) 2004-08-27
NZ533383A (en) 2007-02-23
NO330159B1 (no) 2011-02-28
HRP20040514A2 (en) 2004-10-31
HUP0402217A2 (hu) 2005-01-28
CY1105608T1 (el) 2010-12-22
JP2005515202A (ja) 2005-05-26
KR100941210B1 (ko) 2010-02-10
UA77728C2 (en) 2007-01-15
BR0214757A (pt) 2004-09-14
CO5580776A2 (es) 2005-11-30
NO20042842L (no) 2004-07-05
PL206755B1 (pl) 2010-09-30
AP2004003055A0 (en) 2004-06-30
EA008090B1 (ru) 2007-02-27
PT1453517E (pt) 2006-06-30
CN100540006C (zh) 2009-09-16
MY134422A (en) 2007-12-31
DE60209145D1 (de) 2006-04-20
GEP20063895B (en) 2006-08-10
DE60209145T2 (de) 2006-10-26
HK1072002A1 (en) 2005-08-12
TW200409640A (en) 2004-06-16
WO2003047587A1 (en) 2003-06-12
US6476068B1 (en) 2002-11-05
US20030109514A1 (en) 2003-06-12
US6673805B2 (en) 2004-01-06
CR7362A (es) 2009-02-12
KR20050058278A (ko) 2005-06-16
RO121509B1 (ro) 2007-10-30
SI21493A (sl) 2004-12-31
HUP0402217A3 (en) 2005-11-28
RS50360B (sr) 2009-11-10
ES2258661T3 (es) 2006-09-01
MEP10408A (en) 2011-02-10
CN1612737A (zh) 2005-05-04
IL162348A (en) 2010-11-30
IL162348A0 (en) 2005-11-20
IS7298A (is) 2004-06-03
ZA200404525B (en) 2005-08-15
OA12739A (en) 2006-06-30
EP1453517B1 (en) 2006-02-08
AR037629A1 (es) 2004-11-17
YU59704A (sh) 2006-08-17
AU2002352105A1 (en) 2003-06-17
ATE317260T1 (de) 2006-02-15
US20030109515A1 (en) 2003-06-12
MA27153A1 (fr) 2005-01-03
IS2580B (is) 2010-02-15
EP1453517A1 (en) 2004-09-08
TNSN04104A1 (fr) 2006-06-01
MXPA04005423A (es) 2004-10-11

Similar Documents

Publication Publication Date Title
DK1453517T3 (da) Farmaceutiske formuleringer med platinderivat
NO20033556L (no) Farmasöytiske formuleringer
NO20033384L (no) Farmasoytisk formulering
PT1501534E (pt) Formulacoes farmaceuticas
FI20011478A0 (fi) Farmaseuttinen koostumus
ITTO20010008A0 (it) Formulazione farmaceutica
NO20033785L (no) Farmasöytisk formulering
NO20040125L (no) Enterale formuleringer
AR028204A1 (es) Composiciones farmaceuticas electrohiladas
FI20001749A (fi) Farmaseuttisia koostumuksia
DK1524266T3 (da) Farmaceutisk sammensætning
NO20035627D0 (no) Farmasöytisk formulering
IS7051A (is) Lyfjasamsetningar
FI20022128A0 (fi) Farmaseuttinen koostumus
DE60217390D1 (de) Bicalutamid enthaltende pharmazeutische zusammensetzung
NO20041485L (no) Farmasoytisk formulering omfattende (R)-bicalutamid
DE10291905D2 (de) Pharmazeutische Zusammensetzung
EE200300465A (et) Püridoindolooni derivaatidel põhinevad farmatseutilised kompositsioonid
DE10107261B4 (de) Pharmazeutische Zusammensetzung
EE200200689A (et) Ravimkoostised
NO20041236L (no) Farmasoytisk formulering
SE0102069D0 (sv) Pharmaceutical formulation
SE0101325D0 (sv) Pharmaceutical formulation
SE0103565D0 (sv) Pharmaceutical formulation
SE0102572D0 (sv) Pharmaceutical formulation